Compare GSK Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ALKEM LABORATORIES - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ALKEM LABORATORIES GSK PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 51.6 22.4 229.7% View Chart
P/BV x 11.6 5.4 214.8% View Chart
Dividend Yield % 1.4 0.9 151.9%  

Financials

 GSK PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
ALKEM LABORATORIES
Mar-20
GSK PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,5952,720 132.2%   
Low Rs1,2531,660 75.5%   
Sales per share (Unadj.) Rs184.7697.9 26.5%  
Earnings per share (Unadj.) Rs26.396.1 27.4%  
Cash flow per share (Unadj.) Rs29.2117.3 24.9%  
Dividends per share (Unadj.) Rs20.0025.00 80.0%  
Dividend yield (eoy) %0.81.1 72.3%  
Book value per share (Unadj.) Rs126.3515.2 24.5%  
Shares outstanding (eoy) m169.40119.57 141.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.13.1 418.3%   
Avg P/E ratio x92.222.8 404.6%  
P/CF ratio (eoy) x83.118.7 445.0%  
Price / Book Value ratio x19.24.3 451.4%  
Dividend payout %76.126.0 292.5%   
Avg Mkt Cap Rs m410,626261,879 156.8%   
No. of employees `0005.014.3 34.6%   
Total wages/salary Rs m5,37215,055 35.7%   
Avg. sales/employee Rs Th6,306.75,822.6 108.3%   
Avg. wages/employee Rs Th1,083.11,050.5 103.1%   
Avg. net profit/employee Rs Th898.0802.0 112.0%   
INCOME DATA
Net Sales Rs m31,28183,444 37.5%  
Other income Rs m1,0231,042 98.2%   
Total revenues Rs m32,30484,486 38.2%   
Gross profit Rs m6,00914,734 40.8%  
Depreciation Rs m4862,528 19.2%   
Interest Rs m6651 0.9%   
Profit before tax Rs m6,54012,598 51.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3731,105 214.8%   
Profit after tax Rs m4,45411,493 38.8%  
Gross profit margin %19.217.7 108.8%  
Effective tax rate %36.38.8 413.7%   
Net profit margin %14.213.8 103.4%  
BALANCE SHEET DATA
Current assets Rs m20,06154,960 36.5%   
Current liabilities Rs m14,54332,433 44.8%   
Net working cap to sales %17.627.0 65.3%  
Current ratio x1.41.7 81.4%  
Inventory Days Days5780 71.4%  
Debtors Days Days1472 19.5%  
Net fixed assets Rs m14,34332,710 43.8%   
Share capital Rs m1,694239 708.5%   
"Free" reserves Rs m19,70461,368 32.1%   
Net worth Rs m21,39861,607 34.7%   
Long term debt Rs m21,592 0.1%   
Total assets Rs m39,11399,433 39.3%  
Interest coverage x1,091.020.4 5,357.6%   
Debt to equity ratio x00 0.4%  
Sales to assets ratio x0.80.8 95.3%   
Return on assets %11.412.2 93.4%  
Return on equity %20.818.7 111.6%  
Return on capital %31.921.0 152.3%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m53416,061 3.3%   
Fx outflow Rs m7,0912,483 285.6%   
Net fx Rs m-6,55713,578 -48.3%   
CASH FLOW
From Operations Rs m3,9945,851 68.3%  
From Investments Rs m-1,433-7,414 19.3%  
From Financial Activity Rs m-3,584792 -452.8%  
Net Cashflow Rs m-1,023-731 140.0%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 33.1 30.8%  
FIIs % 23.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 0.0 -  
Shareholders   102,036 68,381 149.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  DISHMAN PHARMA  J.B.CHEMICALS  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS